Dopamine D(1) Receptor Gene Expression Studies in Unilateral 6-Hydroxydopamine-Lesioned Parkinson's Rat: Effect of 5-HT, GABA, and Bone Marrow Cell Supplementation.

PDF's targeted PubMed search provides you with access to journal articles from the last 90 days that may be pertinent to Parkinson's disease research. 

Not what you're looking for? Do you need informational publications about Parkinson's targeted for people living with Parkinson's, caregivers and family members?  Please browse PDF's educational materials and programs - which are all available electronically or in print.  Order for yourself, a loved one or in bulk for your patients or support group.

J Mol Neurosci 2009 Jul;

Authors: M Nandhu, E Fabia, C Paulose

Molecular Neurobiology and Cell Biology Unit, Centre for Neuroscience, Department of Biotechnology, Cochin University of Science and Technology, Kochi, 682 022, Kerala, India.

Parkinson's disease is the second most common neurodegenerative disorder and remains incurable. Many potential compensatory mechanisms have now been proposed; these are both dopaminergic, focused on enhancing effects or exposure to existing dopamine, and non-dopaminergic, being focused on reducing activity of the indirect striatal output pathway. In the present study, the effects of serotonin, gamma-aminobutyric acid, and bone marrow cell supplementation intranigrally to the substantia nigra on unilateral 6-hydroxydopamine-infused rats were analyzed individually. Dopaminergic binding parameters were done by Scatchard analysis of dopamine D(1) receptor-binding assay using [(3)H]SCH 23390. In the corpus striatum, 6-hydroxydopamine-infused rats showed a significant decrease in B (max) (P < 0.001), and in cerebral cortex, they showed a significant increase in B (max) (P < 0.001) compared to control. Real-time polymerase chain reaction amplification of dopamine D(1) was downregulated (P < 0.001) in the corpus striatum of 6-hydroxydopamine-infused rats compared to control, whereas in the cerebral cortex, it showed a significant upregulation (P < 0.001). Behavioral studies were carried out to confirm the biochemical and molecular studies. Serotonin and gamma-aminobutyric acid supplementation reversed these changes to control. The bone marrow cell-treated group of our studies does not show much significant change as compared to the serotonin and gamma-aminobutyric acid-supplemented groups. The alterations in dopamine D(1) receptor-binding parameters and gene expression during Parkinson's model were reversed by serotonin and gamma-aminobutyric acid supplementation in our experiments, which has clinical significance in the management of the disease.

PMID: 19578995 [PubMed - as supplied by publisher]

See More

Back to PubMed Articles